ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

NCT ID: NCT00635284

Last Updated: 2019-10-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-01
• Study Completion Date: 2011-06-01

Brief Summary

To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.

Detailed Description

No extended description necessary

Conditions

Solid Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ABI-009

Group Type: EXPERIMENTAL

ABI-009

Intervention Type: DRUG

nab-rapamycin

Interventions

ABI-009

nab-rapamycin

Intervention Type: DRUG

Other Intervention Names

nab-rapamycin

Eligibility Criteria

Inclusion Criteria

Each subject must meet the following criteria to be enrolled in this study.

1. Male and female patients with histologically or cytologically confirmed diagnosis of cancer which is not amenable to curative therapy.

2. Patients with advanced non-hematologic malignancies for whom no standard therapy exists.

3. Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, pleural effusion, ascites, or lesions which do not fulfill RECIST criteria for metastatic disease)

4. Off all therapy (inclusive of investigational therapies) for at least 4 weeks prior to study drug administration OR off all daily or weekly therapy (inclusive of investigational therapies) for at least 2 weeks prior to study drug administration and without any side effects associated with these therapies.

5. Female patients of child-bearing potential must have a negative serum pregnancy test within 7 days prior to first study drug administration.

6. Female patients who are postmenopausal must have 12 months of amenorrhea, surgically sterile, or must agree to the use of a physical method of non-hormonal contraception.

7. Male patients must be surgically sterile or agree to the use of a barrier method of contraception.

8. Life expectancy of > 3 months.

9. ECOG Performance Status of 0-1.

10. Patients must be able to provide informed consent indicating knowledge of his/her disease process, the investigational nature of the therapy, alternatives, benefits, and risks including potential side effects.

11. Age ≥ 18 years of age.

12. No major surgery within 4 weeks before treatment with ABI-009. (A biopsy is not considered major surgery).

13. No chemotherapy, hormonal therapy, immunotherapy or radiotherapy within 4 weeks before treatment with ABI-009 (6 weeks for previous treatment with nitrosoureas, mitomycin, or extensive radiotherapy) and no immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).

14. No immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).

15. Required Initial Laboratory Data:

• Hemoglobin > 9.0 g/dL
• WBC ≥ 3,000/µl
• ANC ≥ 1,500/µl
• Platelet count ≥ 100,000/µl
• Total Bilirubin ≤ ULN
• SGOT (AST) SGPT (ALT) ≤ 1.5 x ULN ≤ 1.5 x ULN
• Serum Cholesterol < 350 mg/dL
• Serum Triglyceride < 300 mg/dL

16. Adequate renal function with serum creatinine < 1.5 mg/dL and/or creatinine clearance (cockroft formula) ≥ 60 mL/min.

17. No active alcohol abuse, drug addiction, or psychotic disorders.

18. No known concomitant genetic or acquired immunosuppressive diseases (such as AIDS).

19. If obese, a patient must be treated with doses calculated using his/her actual BSA (The physician must be comfortable treating at the full BSA dose regardless of BSA).

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study.

1. Pregnant or nursing women.

2. History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics.

3. Patients have not recovered from adverse affects of radiation therapy or investigational agent within previous 28 days.

4. Uncontrolled intercurrent illness that in the opinion of the investigator would limit compliance and tolerance to study requirements

5. Patients with known brain metastases or leptomeningeal tumor involvement.

6. Receiving any of the following: concomitant antitumor therapy or inhibitors of CYP3A4.

7. Patients with history of interstitial lung disease and/or pneumonitis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ana M. Gonzalez, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Sant P. Chawla, MD

Role: PRINCIPAL_INVESTIGATOR

Sarcoma Oncology Center

Locations

Sarcoma Oncology Center

Santa Monica, California, United States

University of Texas M.D. Anderson Cancer Center

Houston, Texas, United States

Countries

United States

References

Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110.

Reference Type: BACKGROUND

PMID: 24089446 (View on PubMed)

Other Identifiers

CA401

Identifier Type: -

Identifier Source: org_study_id

NCT00573677

Identifier Type: -

Identifier Source: nct_alias